Investor Presentaiton
Investments in "causal human biology to proof-of-concept"
research framework ensure we are industry-leading
•
Causal
human biology
•
Human genetics (germline
•
and somatic)
Translational insights from
patients in the real world and
BMS clinical trials
Matching modality
to mechanism
Diverse modalities, including:
-
Small molecules
Biotherapeutics
Nucleic acid therapies
Targeted Protein Degradation
Cell Therapy
Al-assisted molecule invention
88
Path to clinical
proof-of-concept
Technologies and diagnostics
to enable mechanistic
models for dose, schedule, and
patient populations
"T'EMPUS
FINNGEN
biobank
Open Targets
BROAD
INSTITUTE
Bristol Myers Squibb™
uk
insitro
SCHRÖDINGER.
Exscientia
BigHat
BIOSCIENCES
+
1-8
Not for Product Promotional Use
18View entire presentation